SCHEMBL6427483

SCHEMBL6427483

O=C(c1ccc([N+](=O)[O-])o1)N1CCN(C2CCCCC2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.62
▸ KMT2A Q03164 1/20 0.60
▸ SCN5A Q14524 2/20 0.58
▸ SCN2A Q99250 2/20 0.58
▸ SCN10A Q9Y5Y9 2/20 0.58
▸ CA12 O43570 1/20 0.56
▸ CA1 P00915 1/20 0.56
▸ CA2 P00918 1/20 0.56
▸ CA7 P43166 1/20 0.56
▸ CA9 Q16790 1/20 0.56
▸ L3MBTL1 Q9Y468 3/20 0.56
▸ L3MBTL3 Q96JM7 2/20 0.56
▸ KDM4E B2RXH2 3/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ CHRNA4 P43681 1/20 0.54
▸ SLC2A1 P11166 2/20 0.54
▸ TSHR P16473 1/20 0.53
▸ POLB P06746 3/20 0.51
▸ PKM P14618 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5322339 0.77 ALDH1A1 (1.00) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL6427074 0.76 ALDH1A1 (0.72) ALDH1A1KMT2ASCN5ASCN2ASCN10A
SCHEMBL6428068 0.74 CA12 (0.72) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL6427542 0.74 ALDH1A1 (0.69) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL26706250 0.74 KMT2A (0.70) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL31349311 0.73 POLB (0.76) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL6427505 0.72 ALDH1A1 (0.62) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL6427605 0.72 ALDH1A1 (0.66) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL31349326 0.72 ALDH1A1 (0.66) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL12443384 0.72 ALDH1A1 (0.62) ALDH1A1KMT2ACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050222408-A1 Heterocyclic amides with anti-tuberculosis activity UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-10-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222408-A1 Heterocyclic amides with anti-tuberculosis activity TST, KAT5, NDUFS5 ALDH1A1 2116/4885KMT2A 2545/4885SCN5A 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback